ReportGem ReportGem EN

普通外文研报

Drug Supply Chain: Transparent Pressure: Thoughts on UNH PBM News

发布日期: 2026-05-12研究机构: Deutsche Bank公司 / 股票: CI.N,CVS.N报告页数: 15原文语言: 英语证据页码: 1

研报英文原文证据摘录

Drug Supply Chain: Transparent Pressure: Thoughts on UNH PBM News

Deutsche Bank

Research

North America Industry Date

United States 12 May 2026

Drug Supply Chain

Health Care Industry Update

Healthcare Technology &

Distribution

Transparent Pressure: Thoughts on

UNH PBM News

George Hill

UNH Launching Fee-based PBM Model: Optum Rx announced the launch of

Research Analyst

"Transparent Pharmacy Care Model" this week, which replaces traditional PBM +1-212-250-7822

pricing structures tied to manufacturer list prices and prescription volume with

fixed, clearly disclosed per-member service fees. The model eliminates spread Maxi Ma, CFA

Research Associate

pricing practices, provides clients visibility into Optum Rx and GPO-related fees,

+1-901-338-2175

and includes a commitment to transition group purchasing economics to flat

service fees by the end of 2027. The new cost-based pricing applies to all drugs and Liz Li

pharmacies instead of a small subset, and Optum customers can audit the rebates Research Associate

and fees all the way to the GPO Emisar. The structural change is complemented by +1-617-251-2782

new digital affordability tools, including “Shop MyScript” and “Price Wise,” which

Key Changes

allow consumers to compare medication costs, pharmacy options and delivery

choices before prescriptions are filled. The announcement builds on several recent Company Target Price Rating

Optum Rx initiatives focused on rebate pass-through, reducing both drug and UNH.N 360.00 to -

370.00

medical prior authorizations and restructuring pharmacy reimbursement terms.

The move follows similar transparent PBM model launches from peers, including Source: Deutsche Bank

CVS Caremark’s “TrueCost” initiative introduced in 2024 and Express Scripts’

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器